S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

के लिए वास्तविक समय के अद्यतन Eisai Co., Ltd. [ESALF]

एक्सचेंज: OTC क्षेत्र: Healthcare उद्योग: Drug Manufacturers—Specialty & Generic
अंतिम अद्यतन25 Apr 2024 @ 23:24

0.00% $ 40.01

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 23:24):

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures...

Stats
आज की मात्रा 4.00
औसत मात्रा 1 120.00
बाजार मूल्य 11.48B
EPS $9.72 ( 2023-11-06 )
Last Dividend $0.603 ( 2023-03-30 )
Next Dividend $0 ( N/A )
P/E 39.22
ATR14 $0 (0.00%)

Eisai Co., Ltd. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Eisai Co., Ltd. वित्तीय

Annual 2023
राजस्व: $744.40B
सकल लाभ: $543.48B (73.01 %)
EPS: $193.31
FY 2023
राजस्व: $744.40B
सकल लाभ: $543.48B (73.01 %)
EPS: $193.31
FY 2022
राजस्व: $756.23B
सकल लाभ: $569.79B (75.35 %)
EPS: $167.27
FY 2021
राजस्व: $645.94B
सकल लाभ: $484.63B (75.03 %)
EPS: $146.95

Financial Reports:

No articles found.

Eisai Co., Ltd. Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.555
(N/A)
$0
(N/A)
$0.603
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Eisai Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.00 - Decrease likely (20.04%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.784 2014-03-27
Last Dividend $0.603 2023-03-30
Next Dividend $0 N/A
Payout Date 2018-05-24
Next Payout Date N/A
# dividends 18 --
Total Paid Out $11.60 --
Avg. Dividend % Per Year 0.00% --
Score 2.79 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.00
Div. Directional Score 7.04 --
Next Divdend (Est)
(2024-09-23)
$0 Estimate 0.00 %
Dividend Stability
0.09 Very Bad
Dividend Score
2.79
Pay Frequency
Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
UELMO Ex Dividend Knight 2023-07-20 Quarterly 0 0.00%
JUMSF Ex Dividend Knight 2023-08-23 Semi-Annually 0 0.00%
BTSDF No Dividend Player 2023-09-05 Annually 0 0.00%
RSTRF Ex Dividend Knight 2023-09-19 Semi-Annually 0 0.00%
FFWC Ex Dividend Knight 2023-09-14 Quarterly 0 0.00%
WDFN Ex Dividend Junior 2023-08-10 Quarterly 0 0.00%
MAAL Ex Dividend Knight 2023-09-22 Quarterly 0 0.00%
CLPHY Ex Dividend Knight 2023-09-01 Quarterly 0 0.00%
SMFKY Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
HAWPY Ex Dividend Knight 2023-08-22 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06061.5008.7910.00[0 - 0.5]
returnOnAssetsTTM0.03461.2008.8510.00[0 - 0.3]
returnOnEquityTTM0.05461.500-0.504-0.756[0.1 - 1]
payoutRatioTTM1.011-1.00010.00-10.00[0 - 1]
currentRatioTTM2.380.8003.102.48[1 - 3]
quickRatioTTM1.6970.8004.723.78[0.8 - 2.5]
cashRatioTTM1.0251.5005.428.12[0.2 - 2]
debtRatioTTM0.127-1.5007.89-10.00[0 - 0.6]
interestCoverageTTM25.361.0001.7191.719[3 - 30]
operatingCashFlowPerShareTTM215.912.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM166.262.0010.0010.00[0 - 20]
debtEquityRatioTTM0.203-1.5009.19-10.00[0 - 2.5]
grossProfitMarginTTM0.7891.0000.1760.176[0.2 - 0.8]
operatingProfitMarginTTM0.07901.000-0.419-0.419[0.1 - 0.6]
cashFlowToDebtRatioTTM0.3721.0009.049.04[0.2 - 2]
assetTurnoverTTM0.5720.8009.527.62[0.5 - 2]
Total Score10.08

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM39.991.0006.060[1 - 100]
returnOnEquityTTM0.05462.50-0.324-0.756[0.1 - 1.5]
freeCashFlowPerShareTTM166.262.0010.0010.00[0 - 30]
dividendYielPercentageTTM0.01681.5009.580[0 - 0.4]
operatingCashFlowPerShareTTM215.912.0010.0010.00[0 - 30]
payoutRatioTTM1.0111.50010.00-10.00[0 - 1]
pegRatioTTM0.01621.500-3.230[0.5 - 2]
operatingCashFlowSalesRatioTTM0.08261.000-0.4340[0.1 - 0.5]
Total Score4.00

Eisai Co., Ltd.

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

के बारे में लाइव सिग्नल्स

इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।

लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं